1. Rob ten Hoedt, President of Medtronic Europe, gave a presentation on the medical technology industry and Medtronic's role in innovation in Europe.
2. Key trends in European healthcare include aging populations, rising costs, and a focus on prevention and chronic disease management outside hospitals.
3. Medtronic is developing innovative solutions like implantable devices, biologics, and wireless technologies to treat conditions like heart disease, diabetes, and neurological disorders.
Passing the healthcare innovation torch: from medicinal chemistry, though bio...Martin Sumner-Smith
In the middle of the 20th Century, pharmaceutical companies were highly respected and patients depended on their physicians to make healthcare decisions. Drugs were a key part of a physician’s ‘toolkit’.
As we entered the era of the blockbuster drugs, most were small molecules made by chemical synthesis, but biotechnology was starting to emerge as a possible source of new therapeutics. Meanwhile, direct-to-consumer pharmaceutical advertising began to empower patients.
Fast forward to today, and we see pharmaceutical companies suffering degraded reputations and values, patients further empowered by the Internet and social media, and average life expectancies increased by a decade. Digital health technologies are poised to explode and the top 10 pharmaceuticals by sales will soon all be biologicals!
This document discusses innovations in healthcare and lessons for social service delivery. It outlines four major trends in healthcare innovation: 1) IT innovation using mobile health, big data, and AI, 2) technological innovation including robots, wearables, and 3D printing, 3) service innovation focused on patient-centered care, and 4) business innovation applying lean management and CSR. The future of healthcare is predicted to see more personalization using genomics and wearables, reinforcement of treatment effectiveness through big data and AI, and replacement of biological components with artificial organs or regenerative medicine. Finally, the document suggests social services can learn from healthcare innovations by adopting wearables, IoT, big data, and AI to enable more recipient-focused,
This document summarizes 10 health innovations and trends to watch in 2010, including: 1) "Hello Health" franchised primary care practices with online tools and direct payments, 2) use of surgical checklists to improve safety, 3) mobile health applications like HealthMap for disease surveillance, 4) direct-to-consumer genetic testing providing personalized health information, 5) "reverse innovations" developed first for emerging markets, 6) services generating personalized care plans from health data, 7) point-of-care diagnostic technologies, 8) the University of Toronto's crowdsourcing of health system ideas, 9) the growth of mobile health applications, and 10) patient data sharing communities like PatientsLikeMe. These innovations aim to improve health
Ομιλία - Παρουσίαση: “The Value of Innovation to Patients & Health Systems”
Clare Hague PhD, Therapy Area Market Access Leader for Hematology, Janssen EMEA Region
Evaluation of health technologies in France: from theory to practice cheweb1
1) The document discusses economic evaluation of health technologies in France, outlining reforms that have strengthened the role of the French National Health Board (HAS) in conducting economic assessments.
2) Reforms in 2008 and 2012 gave HAS legal authority to produce economic guidance on pricing for new technologies alongside its clinical assessments.
3) HAS now produces efficiency guidance within 90 days of new technology submissions to inform pricing decisions, assessing expected cost-effectiveness and budget impact.
The document summarizes Steve Halasey's presentation at the 2010 Washington State Biomedical Device Summit on healthcare reform and the future of medical technology innovation. It provides an overview of InHealth, including its mission to fund research on the impacts of medical technology. It discusses InHealth's $11 million in research grants and $1 million+ in educational programs. It then analyzes the Patient Protection and Affordable Care Act and its potential unintended consequences for medical device manufacturers. It stresses the importance of evidence-based research and industry engagement to help shape new agencies and programs under healthcare reform.
Μάκης Παπαταξιάρχης - 6th Clinical Research ConferenceStarttech Ventures
Ομιλία: Μάκης Παπαταξιάρχης, Διευθύνων Σύμβουλος Janssen Ελλάδος, Pharmaceutical Companies of Johnson & Johnson, Πρόεδρος του PhRMA Innovation Forum, Πρόεδρος του AmCham Pharmaceutical Committee
Information Advantage Group Newsletter May 2011HIMSS
Information Advantage Group's Healthcare Digest focuses on emerging models for healthcare delivery from hospitals to consumers. It provides concise, essential news and information on trends, ideas, technology, and resources. Digital media is the primary platform for news, with 41% of people getting information online and 46% accessing news digitally at least three times weekly. Telehealth and remote monitoring are growing areas, as seen in the VA's expansion of these services through large contracts.
Passing the healthcare innovation torch: from medicinal chemistry, though bio...Martin Sumner-Smith
In the middle of the 20th Century, pharmaceutical companies were highly respected and patients depended on their physicians to make healthcare decisions. Drugs were a key part of a physician’s ‘toolkit’.
As we entered the era of the blockbuster drugs, most were small molecules made by chemical synthesis, but biotechnology was starting to emerge as a possible source of new therapeutics. Meanwhile, direct-to-consumer pharmaceutical advertising began to empower patients.
Fast forward to today, and we see pharmaceutical companies suffering degraded reputations and values, patients further empowered by the Internet and social media, and average life expectancies increased by a decade. Digital health technologies are poised to explode and the top 10 pharmaceuticals by sales will soon all be biologicals!
This document discusses innovations in healthcare and lessons for social service delivery. It outlines four major trends in healthcare innovation: 1) IT innovation using mobile health, big data, and AI, 2) technological innovation including robots, wearables, and 3D printing, 3) service innovation focused on patient-centered care, and 4) business innovation applying lean management and CSR. The future of healthcare is predicted to see more personalization using genomics and wearables, reinforcement of treatment effectiveness through big data and AI, and replacement of biological components with artificial organs or regenerative medicine. Finally, the document suggests social services can learn from healthcare innovations by adopting wearables, IoT, big data, and AI to enable more recipient-focused,
This document summarizes 10 health innovations and trends to watch in 2010, including: 1) "Hello Health" franchised primary care practices with online tools and direct payments, 2) use of surgical checklists to improve safety, 3) mobile health applications like HealthMap for disease surveillance, 4) direct-to-consumer genetic testing providing personalized health information, 5) "reverse innovations" developed first for emerging markets, 6) services generating personalized care plans from health data, 7) point-of-care diagnostic technologies, 8) the University of Toronto's crowdsourcing of health system ideas, 9) the growth of mobile health applications, and 10) patient data sharing communities like PatientsLikeMe. These innovations aim to improve health
Ομιλία - Παρουσίαση: “The Value of Innovation to Patients & Health Systems”
Clare Hague PhD, Therapy Area Market Access Leader for Hematology, Janssen EMEA Region
Evaluation of health technologies in France: from theory to practice cheweb1
1) The document discusses economic evaluation of health technologies in France, outlining reforms that have strengthened the role of the French National Health Board (HAS) in conducting economic assessments.
2) Reforms in 2008 and 2012 gave HAS legal authority to produce economic guidance on pricing for new technologies alongside its clinical assessments.
3) HAS now produces efficiency guidance within 90 days of new technology submissions to inform pricing decisions, assessing expected cost-effectiveness and budget impact.
The document summarizes Steve Halasey's presentation at the 2010 Washington State Biomedical Device Summit on healthcare reform and the future of medical technology innovation. It provides an overview of InHealth, including its mission to fund research on the impacts of medical technology. It discusses InHealth's $11 million in research grants and $1 million+ in educational programs. It then analyzes the Patient Protection and Affordable Care Act and its potential unintended consequences for medical device manufacturers. It stresses the importance of evidence-based research and industry engagement to help shape new agencies and programs under healthcare reform.
Μάκης Παπαταξιάρχης - 6th Clinical Research ConferenceStarttech Ventures
Ομιλία: Μάκης Παπαταξιάρχης, Διευθύνων Σύμβουλος Janssen Ελλάδος, Pharmaceutical Companies of Johnson & Johnson, Πρόεδρος του PhRMA Innovation Forum, Πρόεδρος του AmCham Pharmaceutical Committee
Information Advantage Group Newsletter May 2011HIMSS
Information Advantage Group's Healthcare Digest focuses on emerging models for healthcare delivery from hospitals to consumers. It provides concise, essential news and information on trends, ideas, technology, and resources. Digital media is the primary platform for news, with 41% of people getting information online and 46% accessing news digitally at least three times weekly. Telehealth and remote monitoring are growing areas, as seen in the VA's expansion of these services through large contracts.
This document discusses concepts related to the global health-tech industry. It provides an overview of key topics including the healthcare and life sciences industry in 2020, technologies and startups disrupting the status quo, a focus on the medical device industry globally and in India, and a concept note on syringe counterfeiting. The document also analyzes funding trends in 2020, highlights major disruptors like telemedicine, and provides snapshots on medical devices and new anti-counterfeiting technologies.
2018 has finally arrived, and healthcare companies’ executives from both small and big firms have hit the ground running. With technological artificial intelligence and new drugs in the industry, below are 6 healthcare predictions for 2018.
Medical Device Forum Speaker 2015 BerlinGaurav Mishra
This document provides information about the Medical Device AccessLeaders Forum taking place in Berlin, Germany from December 8-10, 2015. The forum consists of 4 events in 1 and will feature keynote presentations from medical device market access leaders and payers/HTA agencies. Day 1 focuses on the international medical device payer and HTA forum. Day 2 will discuss evidence generation for medical devices. Day 3 will have 2 streams, one on market access for surgical/implantable devices and another for diagnostics/capital equipment. The forum will benefit medical device manufacturers, stakeholders, solution providers, and consultants by discussing demonstrating value to payers and obtaining reimbursement.
Medtronic takes advantage of several factors in the medical device industry in which it operates. The incidence of type 1 diabetes is increasing, and active diabetics prefer insulin pumps to injections. However, the Affordable Care Act imposes an excise tax on medical device companies. Medtronic pursues a combination of low-cost and differentiation strategies. It has diversified into related businesses through acquisitions while maintaining its focus on sensing and stimulation technologies. Medtronic has strong financial performance with higher profit margins than competitors. However, the excise tax may reduce industry growth. Over the next 5 years, Medtronic is well-positioned to continue growing through cost improvements and acquiring smaller companies impacted by the tax
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
The Knowledge Transfer Network (KTN) is the UK's innovation network that brings together businesses, academics, entrepreneurs and funders to develop new products, processes and services. The KTN helps businesses grow the economy and improve lives by maximizing the value of innovative ideas, research and creativity. It focuses on priority areas like health technologies, manufacturing, and bioinformatics to diagnose, treat and manage diseases while improving quality of life. The KTN provides support for businesses through funding connections, access to expertise in centers of excellence, assistance developing supply chains, and help navigating complex innovation issues.
The document discusses the potential benefits of eHealth (ICT for health) in Europe. It notes that while the health sector employs over 9% of the EU workforce, ICT penetration in health is relatively low compared to other sectors. eHealth can improve efficiency and productivity, support chronic disease management and preventive care, and empower patients. The EU is a world leader in deploying ICT in primary care settings. Further development of eHealth requires addressing issues like interoperability, business models, and research into areas like personalized medicine.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
Real World Outcomes Across the AD (Alzheimer’s disease) Spectrum (ROADS) to B...Martin Pan
The document describes the Real World Outcomes Across the AD Spectrum (ROADS) topic, which aims to develop recommendations on appropriate outcome measures and data sources to characterize Alzheimer's disease across its spectrum in real-world settings. The project will define patient-relevant outcomes, identify data sources, and provide guidance on modeling disease progression using existing data. This will inform a subsequent prospective data collection effort to generate real-world evidence on AD and optimize care systems. The collaboration involves industry, academic, regulatory, HTA and patient organizations to ensure the work supports evaluation and access to new AD treatments.
This document discusses different perspectives on pricing medicines and value-based pricing approaches. It covers the dilemmas of international reference pricing which can lead to price convergence around the lower end and delays in access to medicines in less wealthy markets. It also discusses the need to consider a holistic perspective of the value of medicines that incorporates economic and social benefits, not just health system costs. Transparency in pricing and procurement is discussed as both an opportunity and risk depending on how it is implemented.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
This document provides an overview of the medical technology industry in 2004. It discusses key topics such as:
- The U.S. medical technology industry was estimated to be a $77 billion market in 2002 and was one of the largest producers and exporters globally.
- Research and development spending was a significant priority for the industry, with firms spending an average of 11.4% of sales on R&D in 2002, more than most other industries.
- Innovation in medical technology was improving patient outcomes by enabling earlier disease detection, more effective treatments and shorter hospital stays, while also generating economic benefits from a more productive workforce.
- The future outlook for the industry was positive, with many promising new
Medicines and vaccines have helped deliver improvements in patient health. History shows us the great advances we have made - today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
The document discusses the importance of manufacturing to the UK pharmaceutical industry and the life sciences sector. It outlines the goals of the Medicines Manufacturing Industry Partnership (MMIP) in making the UK an attractive location for medicines manufacturing through initiatives like skills development programs. The document also notes industry's significant financial contributions to the NHS through the Pharmaceutical Price Regulation Scheme, and the importance of ensuring a regulatory framework that supports innovation as the UK leaves the EU.
The Detection and Identification of Infectious Agents Innovation Platform aims to encourage the development, uptake and adoption of clinically useful and commercially viable diagnostics for detecting infectious agents in humans and animals. The Technology Strategy Board launched the platform in 2008 and will invest up to £50 million over five years, together with additional funding from government departments like the Department of Health. More rapid and accurate diagnosis of infectious diseases can lead to targeted treatments that reduce the social and economic impact of diseases and create opportunities for UK industry.
Information+Integration ? Innovation an HL7/EFMI/HIMSS @eHealthweek2015 in Rigachronaki
Join us to explore “Interoperability in action: information + integration = innovation?” and engage in lively debate on how rethinking interoperability standards and continuing education can bridge divides, change cultures, and open markets!
Perspectives from health management, industry, government, health education, and standardization exemplify challenges and opportunities for liberation of data that can drive desired social and technological innovation.
This is a call for action to explore how the partnership of HL7, EFMI and HIMSS can catalyze the equation “information + integration = innovation” to bridge divides, change culture and open markets.
There are different models for determining the price of medicines, but value-based pricing that considers the outcomes a treatment provides relative to its cost is likely the most appropriate approach. However, current pricing and reimbursement systems face challenges in applying value-based pricing due to uncertainties in data, combination therapies, multi-indication drugs, and ensuring treatments are both cost-effective and affordable for healthcare systems. Fair pricing requires balancing incentives for pharmaceutical innovation with improving access and affordability for patients.
Medtronic is a medical technology company that develops life-changing technologies to treat chronic diseases. They work closely with physicians around the world and have six major business units focused on different medical conditions and therapies. Medtronic serves medical professionals by developing innovative technologies and uses a blend of Lean and Six Sigma practices in their business model. They are constantly innovating both new technologies and business processes to improve patient care and lives.
The world's population is growing larger, older, and sicker, placing increasing challenges on healthcare systems to expand access to care with finite resources. Chronic diseases now account for 70% of illnesses, and the population over 50 will increase by over 500 million by 2025. Healthcare systems face constraints like aging populations, growing disease burdens, and limited budgets. However, new medical technologies in development and advances in data analytics provide optimism for healthier futures. Key questions remain around how to introduce high-value innovations and make systems more sustainable.
This document discusses concepts related to the global health-tech industry. It provides an overview of key topics including the healthcare and life sciences industry in 2020, technologies and startups disrupting the status quo, a focus on the medical device industry globally and in India, and a concept note on syringe counterfeiting. The document also analyzes funding trends in 2020, highlights major disruptors like telemedicine, and provides snapshots on medical devices and new anti-counterfeiting technologies.
2018 has finally arrived, and healthcare companies’ executives from both small and big firms have hit the ground running. With technological artificial intelligence and new drugs in the industry, below are 6 healthcare predictions for 2018.
Medical Device Forum Speaker 2015 BerlinGaurav Mishra
This document provides information about the Medical Device AccessLeaders Forum taking place in Berlin, Germany from December 8-10, 2015. The forum consists of 4 events in 1 and will feature keynote presentations from medical device market access leaders and payers/HTA agencies. Day 1 focuses on the international medical device payer and HTA forum. Day 2 will discuss evidence generation for medical devices. Day 3 will have 2 streams, one on market access for surgical/implantable devices and another for diagnostics/capital equipment. The forum will benefit medical device manufacturers, stakeholders, solution providers, and consultants by discussing demonstrating value to payers and obtaining reimbursement.
Medtronic takes advantage of several factors in the medical device industry in which it operates. The incidence of type 1 diabetes is increasing, and active diabetics prefer insulin pumps to injections. However, the Affordable Care Act imposes an excise tax on medical device companies. Medtronic pursues a combination of low-cost and differentiation strategies. It has diversified into related businesses through acquisitions while maintaining its focus on sensing and stimulation technologies. Medtronic has strong financial performance with higher profit margins than competitors. However, the excise tax may reduce industry growth. Over the next 5 years, Medtronic is well-positioned to continue growing through cost improvements and acquiring smaller companies impacted by the tax
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
The Knowledge Transfer Network (KTN) is the UK's innovation network that brings together businesses, academics, entrepreneurs and funders to develop new products, processes and services. The KTN helps businesses grow the economy and improve lives by maximizing the value of innovative ideas, research and creativity. It focuses on priority areas like health technologies, manufacturing, and bioinformatics to diagnose, treat and manage diseases while improving quality of life. The KTN provides support for businesses through funding connections, access to expertise in centers of excellence, assistance developing supply chains, and help navigating complex innovation issues.
The document discusses the potential benefits of eHealth (ICT for health) in Europe. It notes that while the health sector employs over 9% of the EU workforce, ICT penetration in health is relatively low compared to other sectors. eHealth can improve efficiency and productivity, support chronic disease management and preventive care, and empower patients. The EU is a world leader in deploying ICT in primary care settings. Further development of eHealth requires addressing issues like interoperability, business models, and research into areas like personalized medicine.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
Real World Outcomes Across the AD (Alzheimer’s disease) Spectrum (ROADS) to B...Martin Pan
The document describes the Real World Outcomes Across the AD Spectrum (ROADS) topic, which aims to develop recommendations on appropriate outcome measures and data sources to characterize Alzheimer's disease across its spectrum in real-world settings. The project will define patient-relevant outcomes, identify data sources, and provide guidance on modeling disease progression using existing data. This will inform a subsequent prospective data collection effort to generate real-world evidence on AD and optimize care systems. The collaboration involves industry, academic, regulatory, HTA and patient organizations to ensure the work supports evaluation and access to new AD treatments.
This document discusses different perspectives on pricing medicines and value-based pricing approaches. It covers the dilemmas of international reference pricing which can lead to price convergence around the lower end and delays in access to medicines in less wealthy markets. It also discusses the need to consider a holistic perspective of the value of medicines that incorporates economic and social benefits, not just health system costs. Transparency in pricing and procurement is discussed as both an opportunity and risk depending on how it is implemented.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
This document provides an overview of the medical technology industry in 2004. It discusses key topics such as:
- The U.S. medical technology industry was estimated to be a $77 billion market in 2002 and was one of the largest producers and exporters globally.
- Research and development spending was a significant priority for the industry, with firms spending an average of 11.4% of sales on R&D in 2002, more than most other industries.
- Innovation in medical technology was improving patient outcomes by enabling earlier disease detection, more effective treatments and shorter hospital stays, while also generating economic benefits from a more productive workforce.
- The future outlook for the industry was positive, with many promising new
Medicines and vaccines have helped deliver improvements in patient health. History shows us the great advances we have made - today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
The document discusses the importance of manufacturing to the UK pharmaceutical industry and the life sciences sector. It outlines the goals of the Medicines Manufacturing Industry Partnership (MMIP) in making the UK an attractive location for medicines manufacturing through initiatives like skills development programs. The document also notes industry's significant financial contributions to the NHS through the Pharmaceutical Price Regulation Scheme, and the importance of ensuring a regulatory framework that supports innovation as the UK leaves the EU.
The Detection and Identification of Infectious Agents Innovation Platform aims to encourage the development, uptake and adoption of clinically useful and commercially viable diagnostics for detecting infectious agents in humans and animals. The Technology Strategy Board launched the platform in 2008 and will invest up to £50 million over five years, together with additional funding from government departments like the Department of Health. More rapid and accurate diagnosis of infectious diseases can lead to targeted treatments that reduce the social and economic impact of diseases and create opportunities for UK industry.
Information+Integration ? Innovation an HL7/EFMI/HIMSS @eHealthweek2015 in Rigachronaki
Join us to explore “Interoperability in action: information + integration = innovation?” and engage in lively debate on how rethinking interoperability standards and continuing education can bridge divides, change cultures, and open markets!
Perspectives from health management, industry, government, health education, and standardization exemplify challenges and opportunities for liberation of data that can drive desired social and technological innovation.
This is a call for action to explore how the partnership of HL7, EFMI and HIMSS can catalyze the equation “information + integration = innovation” to bridge divides, change culture and open markets.
There are different models for determining the price of medicines, but value-based pricing that considers the outcomes a treatment provides relative to its cost is likely the most appropriate approach. However, current pricing and reimbursement systems face challenges in applying value-based pricing due to uncertainties in data, combination therapies, multi-indication drugs, and ensuring treatments are both cost-effective and affordable for healthcare systems. Fair pricing requires balancing incentives for pharmaceutical innovation with improving access and affordability for patients.
Medtronic is a medical technology company that develops life-changing technologies to treat chronic diseases. They work closely with physicians around the world and have six major business units focused on different medical conditions and therapies. Medtronic serves medical professionals by developing innovative technologies and uses a blend of Lean and Six Sigma practices in their business model. They are constantly innovating both new technologies and business processes to improve patient care and lives.
The world's population is growing larger, older, and sicker, placing increasing challenges on healthcare systems to expand access to care with finite resources. Chronic diseases now account for 70% of illnesses, and the population over 50 will increase by over 500 million by 2025. Healthcare systems face constraints like aging populations, growing disease burdens, and limited budgets. However, new medical technologies in development and advances in data analytics provide optimism for healthier futures. Key questions remain around how to introduce high-value innovations and make systems more sustainable.
Advanced health technologies and their budgetary implications - Valérie Paris...OECD Governance
This presentation was made by Valérie Paris, OECD Secretariat, at the 6th meeting of the joint OECD DELSA-GOV network on fiscal sustainability of health systems held in Paris, on 18-19 September 2017
Advanced health technologies and budgetary implications -- Valerie Paris, OECDOECD Governance
This presentation was made by Valérie Paris, OECD Secretariat, at the 6th Meeting of the Joint OECD DELSA-GOV Network on Fiscal Sustainability of Health Systems, held at the OECD Conference Centre, Paris, on 18-19 September 2017
Health innovation through new medicines can benefit patients, healthcare systems, and societies in several ways:
1. Patients live longer, healthier lives with access to innovative treatments for diseases like cancer.
2. Healthcare systems see reduced costs in other areas like hospitalizations as innovative medicines treat diseases more effectively.
3. Societies benefit as individuals are able to continue being productive members of their communities through return to work after illnesses.
However, current healthcare challenges include aging populations, rising costs, and constrained budgets. Ensuring access to innovation requires strategies like improving public health, maximizing generic competition, implementing health technology assessments, and embracing organizational innovation in healthcare systems.
DHL_LSH_Europe_Whitepaper_MedicalDevices_WebIan Moore
The document discusses the challenges facing the European medical device supply chain. It notes that the industry is facing pressures from the transition to value-based healthcare with more decision makers involved, intensifying cost pressures from payers looking to reduce costs, and stricter regulations. The supply chain must transform to address these challenges by becoming more efficient and tailored to better meet the needs of all decision makers while also reducing costs.
The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Union and the pharmaceutical industry that aims to boost pharmaceutical innovation in Europe. IMI supports pre-competitive research to accelerate the development of safer and more effective medicines through collaboration between stakeholders like industry, academia, patient organizations, and regulators. IMI is funded jointly by the EU and EFPIA members, with EU funds exclusively supporting public and nonprofit organizations and SMEs.
The medical technology industry faces three fundamental challenges according to the document.
1) Sustaining innovation is challenged by increased regulatory hurdles, capital constraints, and pricing pressures at every stage from idea to commercialization.
2) Delivering value and outcomes is increasingly important as purchasing decisions consolidate, comparative effectiveness research rises, and higher bars are set to bring products to market.
3) Fueling growth requires diversifying products, geographies, and offers including emphasizing outcomes, lower-cost emerging market products, and managing spending jointly with hospitals and insurers.
Overcoming Fear of Health Technology Programsbartlettc
This document summarizes a presentation given by Prof. Mukesh Haikerwal and Chris Bartlett on using 21st century tools to overcome challenges in healthcare. It discusses how health technology programs have had some success but also poor publicity. Rising healthcare costs are challenging many countries. While developing economies spend less on healthcare currently, that spending is expected to increase with economic development. There is a need to better manage chronic diseases through tools like eHealth. New technological trends are impacting all parts of the healthcare system. Successful eHealth programs require leadership, a focus on users, and addressing behavioral changes.
mHealth Israel: PwC emerging mhealth paths for growthLevi Shapiro
Emerging mHealth holds great potential to improve healthcare access, costs and quality through ubiquitous mobile devices. However, widespread adoption faces challenges from healthcare's resistance to change and the need to navigate complex, fragmented systems. Expectations for mHealth are high among patients, doctors and payers, but most experts expect slower adoption as improving patient care often disrupts traditional models. Emerging markets are pioneering mHealth by leaping ahead through greater needs and fewer barriers, showing the path could be smoother where systems are less rigidly established.
1. Medical technology provides substantial benefits to patients' quality of life, disability levels, and mortality rates compared to traditional treatments like drugs alone.
2. While medical technology increases direct health care costs, it also provides significant economic and productivity benefits to society by reducing time lost from work and increasing overall welfare.
3. Studies show that many medical technologies reduce overall lifetime health care costs and societal costs compared to traditional treatments due to better health outcomes and shorter hospital stays.
The document discusses the current state and expected growth trends of the in vitro diagnostics (IVD) market. It notes that the global IVD market was estimated at $54.2 billion in 2013 and is expected to grow 4% annually to $64.3 billion by 2018. Technological advances in areas like genomics, bioinformatics, and miniaturization have transformed diagnostic laboratory technology in recent years. Personalized medicine, infectious disease testing, and other applications are driving growth in the IVD market. However, economic instability, rising healthcare costs, and reimbursement changes pose challenges for the industry.
Modern medical technology can contribute to achieving a sustainable healthcare system through value-based innovation. The medical technology industry in Europe is large, employing many people and investing heavily in research and development. However, aging populations are increasing healthcare costs and straining budgets. The industry recognizes it needs new business models focused on improving health outcomes and reducing costs to better support sustainable healthcare systems into the future. Value-based innovation that addresses both patient and system needs can help systems adapt to challenges through greater efficiency and productivity.
We don’t have a functional competitive market in health care in the U.S. Consequently, many of the attributes of competitive markets that are beneficial in our lives are not present in health care. One significant negative externality of a dysfunctional market is an inability to discern quality. Consumerism is critical. Includes data and analysis from the 5TH ANNUAL HEALTHGRADES PATIENT SAFETY IN AMERICAN HOSPITALS STUDY – APRIL 2008
The document discusses 10 megatrends shaping healthcare and healthcare IT over the next 5-10 years based on a meta-analysis of several leading sources. The megatrends are organized into three groups: medicine, politics and society, and technology. Some of the key megatrends discussed include the rise of telemonitoring of patients, personalised medicine enabled by electronic health records, aging populations in western countries, increasing healthcare costs requiring value-based approaches, medical tourism and globalization, the growth of cloud computing and mobile technologies, and emerging fields like robotics and nanotechnology.
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
The document discusses current challenges and future trends in clinical development from the perspective of a CRO. It notes that the global CRO market is large but fragmented, and outlines pressures on the pharmaceutical industry like high R&D costs, patent expirations, and regulatory demands. The text also examines trends towards more global, efficient trials using new technologies and less traditional geographies to address these challenges. It argues that collaboration between industry, regulators and CROs will be key to transforming clinical research methods.
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
The document discusses current challenges and future trends in clinical development from the perspective of a CRO. It notes that the global CRO market is large but fragmented, and outlines pressures on the pharmaceutical industry like high R&D costs, patent expirations, and regulatory demands. The text also examines trends towards more global, efficient trials using new technologies and less traditional geographies to address these challenges. It argues that collaboration between industry, regulators and CROs will be key to transforming clinical research processes to increase competitiveness and innovation.
The document outlines the opportunities and challenges presented by big data in healthcare. It notes that vast amounts of data are now being generated from sources like genome sequencing, electronic health records, social media, and patient websites. However, simply having large datasets does not guarantee value; the data needs to be analyzed and linked together to generate insights. The document discusses four levels of big data applications from processing large volumes of data to complex modeling. It also examines challenges like developing robust governance, embracing new data uses, overcoming data fragmentation, ensuring data quality and standards, developing innovative analytic methods, addressing skills shortages, and achieving returns on investment. The goal is to improve patient outcomes and healthcare cost-effectiveness through big data.
Similar to Health Valley Event Presentatie Rob ten Hoedt (20)
Health and fitness apps and devices collect users' personal data, but it is unclear how user data is monetized and who earns from it. A proposed solution is a personal health record platform with an open app store that crowd-sources app development and takes a percentage of app store revenues, while providing platform-level privacy and easy data access. This could form the basis of a new business model for personal health and healthcare data.
This document discusses using ELISA without washing steps by developing a switchable reporter enzyme system. It describes tuning a beta-lactamase enzyme and its inhibitor protein to have high affinity binding and then using this system for wash-free ELISA assays. The goal is to create assays that are faster and require less hands-on time by eliminating washing steps traditionally required in ELISA.
Jack Schalken has co-founded two companies - NovioGendix in 2006 and Oncodrone in 2013 - to translate his translational research into clinical applications and products. As an "entrepreneurial scientist", he learned important lessons about negotiating terms with his academic institution, building a management team, securing financing, and acquiring business skills to successfully launch and grow these ventures. Both companies have worked to bridge the gap between research and clinical validation or product development for cancer diagnostics and therapeutics.
Health Valley Event 2014: Marieke Hettinga, Windesheim
Health Valley Event Presentatie Rob ten Hoedt
1. Health Valley Event De Vereeniging te Nijmegen 16 th March 2011 Rob ten Hoedt President Medtronic Europe
2.
3.
4. New Recognition: Value of EU MedTech – EU Commission «Exploratory Process» 2009-10 1. Public health challenges Holistic approaches Scope and role of Medical Devices sector Public health policies Involvement, education and training of the different actors Patient Safety & Quality of Care Fight against counterfeit medical devices 2. Encompassing innovation 3. Value of and access to medical devices 4. Industrial challenges Innovative technologies/products Involvement for innovation Procurement procedures and reimbursement Research and development Market Availability Measuring value of medical devices technologies Inclusion of medical devices within the scope of the national health insurance systems and funding systems Public procurement Late payments Generation of data Information to patients and clinical practices Global context for research investments FINANCIAL CHALLENGES Industrial environment Regulatory framework Involvement in decisions on access Patient empowerment Transparency Governance in the evaluation and decision making processes “ The Exploratory Process strongly endorsed the need for a clear political vision of the role of the medical device sector in the health of citizens and the economy. … the European Union should act to make Europe the global leader for medical devices by promoting innovation, efficiency and sustainable health outcomes. … A strong medical device sector in Europe will play a central role in supporting the broader EU aspiration that citizens live a longer and healthier life.”
5. Key Trends in European Healthcare Environment Increased focus on prevention Increasing expectations of citizens Increase of chronic and multiple diseases Shift from public to private funding Shift to community and homecare Increasing role of purchasing & paying institutions Declining “power” of healthcare professionals Increasing e-solutions Increased demand for medical technology and services * Ageing populations * Budget deficits * Growing shortage of healthcare workers
6.
7. MedTech Represents a Small % of Total Healthcare Spending Source: Espicom; WHO; World Bank, LEK analysis Medical devices represent <5% of overall spend and offer limited potential cost savings Huge opportunities elsewhere Devices Pharma Operating and other costs 0 100 80 20 60 40 CY08 Device Spending as a % of Total HC 4% 3% 3% 3% 3% 2% 2% 2% 4% 5% Sweden US Hong Kong Taiwan UK Singapore Canada Germany Norway China 2 3 1
8.
9.
10.
11. Brussels, 28 January 2011 – A report of the Boston Consulting Group (BCG) shows medical device recalls in the U.S. and Europe occur at the same rate while the approval process in Europe is significantly faster. The decentralised oversight in Europe, which is the essence of the regulatory system, allows people to benefit from the latest innovative products while guaranteeing the highest level of patient safety and fostering innovation. The findings of the BCG report are in line with an earlier report by Dr. Josh Makower, one of America’s leading medical technology entrepreneurs, which detailed how patients in Europe get access to new therapies an average of two years before patients in the United States due to regulatory challenges at the FDA. By analysing publically available data on severe recalls of medical devices in Europe (equivalent to a Class I recall in the US) the study shows that the number of recalls in Europe is identical to that in the United States, and the therapeutic mix and type of recall is also similar to that in the US. The report states that ‘this initial assessment of comparable recalls between the US and Europe does not suggest that different approval processes, and earlier approvals, in Europe come at a cost in terms of patient safety’. In reaction to the study John Wilkinson, Chief Executive of Eucomed comments: “This is the second study within the last few months that clearly indicates that the current EU regulatory system makes innovative medical technology available to people the fastest in the world while ensuring the highest safety standards. We are currently in the process of a recast of the EU medical device legislation and we believe that the current concept of decentralised oversight must remain. The notified body based system requires improvements in implementation but the system does not need a major overhaul. This BCG study shows that the regime of certification with CE marking has given patients and consumers in Europe the fastest access to the most innovative devices with the highest quality and safety standards in the world.” The report was prepared by Scott Davis, Erik Gilbertson and Simon Goodall of The Boston Consulting Group, a global business management consulting firm, and sponsored by Advamed, the U.S. Advanced Medical Technology Association. Eucomed: Research shows medical device recalls in Europe and U.S. are at similar rates
12.
13. Founded in 1949 as a Minnesota Medical Equipment Service Company
14. Manufacturing and R&D Minneapolis, U.S.A. Tolochenaz, Switzerland Tokyo, Japan Galway, Ireland Puerto Rico Tijuana, Mexico Montréal, Canada Neuchâtel, Switzerland Netanya, Israel Kerkrade & Maastricht, The Netherlands Fourmies & St. Aubin, France Deggendorf, Germany U.S.A. Irvine, CA Los Angeles, CA Memphis,TN Santa Rosa, CA Danvers, MA Jacksonville. FL Sunnyvale, CA Santa Barbara, CA San Antonio, TX Fort Worth, TX 40,000 Medtronic Employees 120 countries
15. CHRONIC DEGENERATIVE DISEASES IMPLANTS >6 million patients/year $1.5 Billion/ yr on R&D Parkinson ’s Disease Essential Tremor Chronic Pain Gastroparesis Urinary Incontinence Dystonia Spasticity
16.
17.
18. Demographics Drive Demand As the Average Age of the Population Is Increasing… % of Population Over 65 Years of Age 2004 2040 Source: World Health Organization 25% 31% 32% 36% 40% 40% 17% 21% 21% 25% 25% 26% 0% 10% 20% 30% 40% 50% US UK France Germany Italy Japan
19.
20. The Burden of Chronic Disease Nearly Half of the Western World population will have Chronic Conditions by 2030 Partnership for Solutions 2004, Chronic Conditions: Making the case for ongoing care
21. Chronic Diseases Have Staggering Costs Chronic Conditions Account for 83% of Health Care Spending Partnership for Solutions 2004, Chronic Conditions: Making the case for ongoing care
40. MD Start Validation Process MD Start ability to accelerate the development process cheaply and quickly will help leap over the ‘funding gap’ between early stage ideas and current expectations for A round financing
44. 2 ways to capture European Innovation 1. Medtronic EUreka Medtronic’s centralized, streamlined process to capture and evaluate physician ideas in Europe across all therapeutic areas Inventor ideas that are not a fit for MDT may be reevaluated by MD Start 2. MD Start An independent incubator co-founded by MDT and other partners (including VC) to bring med tech innovations forward for further investment OR Physician/Inventor ideas
45. Medtronic EUreka Evaluation Process 1. Submit Your Idea Through www.MedtronicEUreka.com Immediate email confirmation 2. Your idea is shared with the appropriate therapy area evaluation team If more info is needed, they’ll contact you 3. We’ll let you know our decision on your idea as soon as we can You’ll hear from us within 3 months 4. If your idea is a “Fit” with MDT we’ll start to work with you on the next steps to develop your idea into reality If not, we can also share your idea with MD Start…
47. How EUreka’s success is measured # pages views # submissions # ideas transfered to MD Start # EUreka sourced ideas pursued by MDT In the past quarter: Nearly 60,000 60 18 More that 25,000 website visits 2 since EUreka launch More that 25,000 website visits
49. It takes more than “just” product innovation to bring solutions to the Health Care Systems
50.
51.
52. We leverage therapy expertise, process improvement techniques and collaboration with best practice networks to optimize care pathways Implement, pilot and institutionalize new process Identify opportunities and design blue print Heart failure therapy management Neuro stimulation enabled pain management Syncope diagnostic and management Aortic aneurysm treatment management … Diagnose current state and baseline performance Readiness
53.
54. Current care pathways are often ineffective and inefficient, as illustrated by the “PICTURE” registry Patients see in average 3 different specialists for their syncope mgt 13 tests performed per patient in the total study population (median #) … and still one third of patients remain undiagnosed Total recruitment 570 (100%) Standard ECG 556 (98%) Echocardiography 490 (86%) Basic laboratory tests 488 (86%) Ambulatory ECG monitoring 382 (67%) In-hospital ECG monitoring 311 (55%) Exercise testing 297 (52%) Orthostatic blood pressure 275 (48%) MRI / CT scan 267 (47%) Neuro. or psy. evaluation 270 (47%) EEG 222 (39%) Carotid sinus massage 205 (36%) Tilt test 201 (35%) Electrophysiology testing 144 (25%) Coronary angiography 133 (23%) External loop recording 67 (12%) ATP test 15 (3%) Other tests 52 (9%) No tests performed 1 (0%)
55. Handicraft culture vs. Industrial culture Ownership Individual Company Product development Integrated Separated Knowledge transfer Personal Explicit Collaboration Interdisciplinary Cross disciplinary Decision Individual Evidence based Value Procedure Product Treatment Tailor-made Standardized Handicraft Industry
56.
57.
58.
Editor's Notes
Medical Devices account for >5% of total healthcare spending in all the countries analyzed In contrast, operational expenses comprise a much higher proportion of overall costs, often over 80% of total spending
One increasingly important group of “customers” are HTA agencies that are demanding to see evidence of the clinical and economic value that our products bring, as a condition for recommending they be used in their respective health care system. HTA agencies have been proliferating in Europe and elsewhere around the world for over 10 years. We have a team of professionals who build working relationships with established and emerging HTA agencies, engage with them when they review our products, and influence HTA policy to ensure it is appropriately tailored to medical devices (as opposed to pharmaceuticals).
Like the NHS, Medtronic is celebrating its 60 th year
Innovation
Insatiable demand for an inelastic good that appears to be “free” Health care costs expected to compound at 7-8%
MD Start’s mission is to accelerate the development of revolutionary medical devices. MD Start provides inventors with a way to develop their ideas without having to abandon their patient or their research.
After you submit to our portal you will receive a confirmation email. Your submission will be shared with the appropriate therapy area leaders across Medtronic. If more information is needed to proceed with your idea, we will contact you using the contact details you provide on the submission form. We will review submissions as they come in and will get back to you as soon as we can, but at the latest we will inform you of our decision within 3 months. If we are interested in pursuing the development of your idea, you will receive a notification and you will be contacted directly by the appropriate therapy leaders within Medtronic. If, after review, your idea cannot be pursued by Medtronic at this time, you will also be notified. It is up to you if you want MDT to share your idea with MD Start, you can always say no thanks
Syncope is technically defined as a transcient, self limited loss of consciousness, usually leading to collapse. The onset is relative rapid and the recovery usually prompt. The underlying mechanism is transient global cerebral hypoperfusion. In simple language, syncope is a sudden blackout / T-Loc which is normally brief, does no permanent damage and which arises from a temporary reduction in the blood supply of the brain. Three main causes for blackouts: cardiovascular (insufficient blood reaches the brain), Neurological (ex. Diseases such as epilepsy), psychogenic (resulting from psychological disorder) Syncope can result from many cardiovascular causes: -cardiac causes - Structural heart diseases - Heart rhythm problems - Vascular causes - Reflex causes - Situational causes (coughing, straining, dehydration, …) - Postural causes (standing up too quickly)
The first specialist consulted for syncope in almost 23% of patients was an emergency medicine consultant. Cardiologists were the first specialists consulted in 43% of cases and neurologists in 11%. The last specialist consulted before the referral for implant of the ILR was a cardiologist in 72% of cases, with no other specialties represented in more than 10% of cases. Cardiologists were the most frequently consulted specialists, with general practitioners second-most consulted physicians overall. Forty-seven per cent of the study population had consulted a neurologist at some point. Overall, patients had seen an average of three different specialists for management of their syncope. The median number of tests performed per patient in the total study population was 13. The tests performed most frequently were echocardiography, ECG, ambulatory ECG monitoring, in-hospital ECG monitoring, exercise testing, and orthostatic blood pressure measurements. About half the patient population had undergone an MRI/CT scan (47%), neurological or psychiatric evaluation (47%), or electroencephalography (EEG; 39%). In contrast, carotid sinus massage or tilt tests were only undertaken in one-third of subjects. The ILR was implanted during the initial phase of the diagnostic work-up (up to four diagnostic tests) in 128 patients (22%). In PICTURE, the EEG rates are most likely explained by the high percentage of referrals to neurologists. The clinical picture of syncope frequently includes neurological symptoms and is often mistaken for epilepsy, which probably explains why neurologists are frequently consulted. Conversely, epilepsy may be mistaken as syncope, but in such patients a Reveal may be a faster way to arrive at the correct diagnosis, if a Reveal recording can be obtained during a typical episode.Furthermore, almost half the patient population had undergone an MRI / CT scan, neurological or psychiatric evaluation. There were, however, simple diagnostic tests that could have been used more widely and would have been included in the initial phase of evaluation, e.g. carotid sinus pressure and orthostatic blood pressure measurements.